EPICS Breast Cancer 2020
Expert Perspectives on Clinical Approaches
Faculty Chair
Adam Brufsky, MD, PhD
Medical Director, Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA
Faculty Members
Jame Abraham, MD
Cleveland Clinic, Cleveland, OH, USA
Peter Kaufman, MD
University of Vermont Cancer Center, Burlington, VT, USA
Mark Pegram, MD
Stanford Cancer Institute,
Stanford, CA, USA
William J. Gradishar, MD, FASCO, FACP
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
Virginia Kaklamani, MD, DSc
UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA
Jasgit C. Sachdev, MD
Translational Genomics Research Institute, Scottsdale, AZ, USA
Monica Fornier, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
Rita Nanda, MD
University of Chicago Hematology Oncology, Chicago, IL, USA
Hope Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
PROGRAM OVERVIEW
In May 2020, Aptitude Health conducted a series of 3 online breast cancer expert forums focused on advances in HER2+ early stage breast cancer and current standards of care. The sessions will be chaired by Adam Brufsky, MD, PhD, Magee-Womens Cancer Program at the UPMC Hillman Cancer Center, Pittsburgh, PA, USA. Life science partners have the ability to silently observe these important and timely online faculty discussions and to receive a comprehensive summary report including customized content specific to their products and areas of expertise.
KEY DISCUSSION TOPICS
- New Standards of Care in HER2+ Early Stage Breast Cancer
- Maximizing Patient Outcomes in HER2+ MBC
- Current and Investigational Approaches in Triple-Negative Breast Cancer
- Evolving Treatments and New Developments in HR+ Metastatic Breast Cancer
- Clinical Management of HR+ Early Stage Breast Cancer
3 VIRTUAL INTERACTIVE SESSIONS
Day 1 | EPICS Advisory Board Session 1
The faculty consisting of top breast cancer experts shared their views via a 3-hour interactive virtual discussion on the newest clinical data, current treatment approaches, and their vision for how the landscape is likely to change in the future. Each clinical data presentation will be followed by a moderated discussion. During this first EPICS session, all stages of HER2+ breast cancer were discussed.
Day 2 | EPICS Advisory Board Session 2
The clinical expert faculty shared their views during a 3-hour virtual discussion on the newest clinical data and treatment evolutions specific to hormone-receptor positive and triple-negative disease. Each presentation on the latest clinical data was followed by a moderated discussion and recommendations from the group regarding current approaches in this patient population.
Day 3 | OncoBoard Discussion Platform Session 3
As a follow-up to the 2 expert advisory sessions, a select group of faculty members revisited some of the key topics related to current treatment paradigms and controversies in breast cancer via the ONCOBOARD platform. ONCOBOARD provided life science companies a closed collaborative online platform for rapid answers to follow-up questions coming out of the first 2 sessions.
